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Unrelated marrow transplantation for adult patients with poor-risk acute
lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors
determining outcome
Jan J. Cornelissen, Michael Carston, Craig Kollman, Roberta King, Adriaan W. Dekker, Bob Lo¨wenberg, and Claudio Anasetti
Between 1988 and 1999, 127 patients with
poor-risk acute lymphoblastic leukemia
(ALL) received a matched unrelated do-
nor transplant using marrow procured by
National Marrow Donor Program (NMDP)
collection centers and sent out to 46
transplant centers worldwide. Poor risk
was defined by the presence of the trans-
locations t(9;22) (n 5 97), or t(4;11)
(n 5 25), or t(1;19) (n 5 5). Sixty-four pa-
tients underwent transplantation in first
remission (CR1), 16 in CR2 or CR3, and 47
patients had relapsed ALL or primary
induction failure (PIF). Overall survival at
2 years from transplant was 40% for pa-
tients in CR1, 17% in CR2/3, and 5% in PIF
or relapse. Treatment-related mortality
(TRM) and relapse mortality, estimated as
competing risk factors, were 54% and 6%,
respectively, in CR1, 75% and 8% in CR2/3,
and 64% and 31% in PIF or relapse. Cur-
rently 23 CR1 patients are alive and free
of disease with a median follow-up of 24
months (range, 3-97). Multivariable analy-
sis showed that CR1, shorter interval
from diagnosis to transplantation, DRB1
match, negative cytomegalovirus (CMV)
serology (patient and donor), and pres-
ence of the Philadelphia chromosome,
t(9;22), were independently associated
with better disease-free survival (DFS).
Transplantation in CR and presence of
t(9;22) were associated with lower risk of
relapse. Shorter interval from diagnosis
to transplantation, DRB1-match, negative
CMV, higher marrow cell dose, and Karnof-
sky score of 90 or higher were associated
with less TRM. These results indicate
that, despite a relatively high TRM, the
low relapse rate resulted in a 37% 6 13%
DFS for CR1 patients, comparing favorably
to results obtained with chemotherapy alone
and matching results following HLA-identi-
cal sibling transplantation. (Blood. 2001;97:
1572-1577)
© 2001 by The American Society of Hematology
Introduction
Long-term disease-free survival (DFS) for adult acute lymphoblas-
tic leukemia (ALL) has only moderately improved during the last 2
decades despite more intensive induction and postinduction therapy
and better supportive care facilities.1-3 Several characteristics have
emerged as high-risk factors in adult ALL, such as high white blood
cell (WBC) counts, older age, late complete remission (CR),
B-lineage immunophenotype, and chromosomal abnormalities.4-9
Recent multicenter studies confirmed that the outcome of patients
with Philadelphia (Ph) chromosome-positive t(9;22) ALL remains
invariably poor with a DFS at 2 years of only 10% to 15%.5-12 The
translocation t(9;22) occurs in approximately 25% of adult ALL
and its incidence increases with age. Other translocations in
B-lineage ALL such as t(4;11) and t(1;19) occur less frequently, but
may also be associated with a poor prognosis.8,11
Although up to 70% of patients may achieve CR after induction
chemotherapy, long-term DFS has remained poor due to a high rate
of relapse. Only allogeneic bone marrow transplantation (BMT)
applied as consolidation therapy in first remission (CR1) was
associated with higher DFS.13-19 Retrospectively collected data of
HLA-identical sibling BMT in Ph1 ALL from the International
Bone Marrow Transplant Registry (IBMTR)14 suggested that DFS
after allogeneic BMT might improve to 38%, which findings were
confirmed by the City of Hope group, which showed a DFS of
approximately 50% at 2 years.13,15,16,19 However, HLA-identical
sibling donors are available for only a limited number of patients.
Alternatively, HLA-matched unrelated donors have been used with
increasing frequency as allogeneic donors for patients with high-
risk acute leukemia.20,21 Currently, only limited data are available
showing results of unrelated BMT in poor-risk ALL. Here, we
report results from 127 transplantations performed between 1988
and 1999 with grafts identified and procured by the National
Marrow Donor Program (NMDP) for adult patients with poor-risk
ALL. It is shown that outcome in patients in CR1 compares
favorably to what can be observed with chemotherapy alone and
matches current results with HLA-identical sibling donors.
Patients and methods
Patients
The study population consisted of 127 adult patients with poor-risk ALL at
46 transplant centers worldwide, who received marrow transplants facili-
tated by the NMDP between 1988 and April 1999. Patients, donor, and graft
characteristics are shown in Table 1. Poor-risk ALL was defined by the
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presence of the translocation t(9;22), or t(4;11), or t(1;19). Ph1 ALL with
t(9;22) represented the majority of patients studied (n 5 97, 76%). Diagno-
sis was based on cytology, karyotype, and immunophenotyping of marrow
cells at diagnosis. Patients had received induction and consolidation
chemotherapy according to local protocols and proceeded to unrelated
donor transplantation according to indications of the individual transplant
center. Protocols were approved by local institutional review boards and all
patients provided written or oral informed consent.
Characteristics are presented according to remission status at transplant,
including 64 patients in CR1, 16 patients in subsequent remission, and 47
patients with primary induction failure (PIF) or relapsed ALL (Table 1). The
median age was 32 years for the whole group of patients. Relatively more
patients in CR2 or CR3 showed either t(4;11) or t(1;19) (P 5 .03) than
patients in CR1. Higher Karnofsky scores were present among patients in
CR1, whereas the majority of refractory patients had Karnofsky scores
below 90 (P , .0001). Refractory patients had presented with higher WBC
at diagnosis and higher percentage of marrow blasts at the time of BMT.
Time from diagnosis to BMT did not differ significantly between patients in
CR1 and refractory patients, but patients in CR2 and CR3 received their
transplant significantly later (7 versus 19 months, P , .0001). Survival,
DFS, relapse, and treatment-related mortality (TRM) were similar among
patients with primary induction failure or relapsed ALL. Therefore, these
patients were analyzed as one group of patients with refractory ALL.
Donor marrow and transplantation
Unrelated donor marrow was provided by 48 donor centers associated with
the NMDP. Marrow cells were harvested according to the policies of the
NMDP and transferred by courier to the transplant center. Donor selection
was based on HLA serotyping performed for HLA-A and -B and a
combination of serotyping and genotyping for HLA-DRB1 according to
standard procedures. Donor and recipient pairs were considered matched
when identical at HLA-A, -B, and -DRB1 loci. Mismatches included at
least one disparity at one of these loci. Graft manipulation was at the
discretion of the transplant center. Thirty-three patients received a T-cell–
depleted (TCD) graft. Methods of T-cell depletion included antibody and
complement-mediated T-cell depletion (n 5 9), elutriation (n 5 8), immu-
nomagnetic beads (n 5 7), sheep red blood cell rosetting (n 5 6), and other
(n 5 3). Patients receiving TCD marrow were infused with a median
number of 0.7 3 108 nucleated cells (NC)/kg body weight (recipient)
(range, 0.1-3.6). Patients with non-TCD grafts received a median number of
2.8 3 108 NC/kg (range, 0.2-8.1). Conditioning for BMT consisted of
regimens based on total body irradiation (TBI) in 115 patients. Etoposide or
cytarabin was added to the combination TBI and cyclophosphamide in 34
patients. Twelve patients received chemotherapy only. Antilymphocyte
globulin (ALG) was added for prevention of rejection in 15 patients.
Supportive care measures were according to local protocols.
End points and statistical analysis
Standard NMDP forms were used for data collection, including pretrans-
plant information, peritransplant events, and short-term and long-term
follow-up. Short-term and long-term data were available for 125 patients.
End points included engraftment, graft-versus-host disease (GVHD),
overall survival (OS), TRM, and relapse. These end points were estimated
for 125 patients; 2 CR1 patients were excluded from these analyses because
Table 1. Patient and donor characteristics
Parameter
First remission
(n 5 64)
2nd, 3rd remission
(n 5 16)
Refractory
(n 5 47) P value
Median age (y)
Recipient (range) 31 (16-54) 27 (17-51) 36 (19-51) .22
Donor (range) 38 (22-58) 30 (20-47) 35 (22-55) .07
Gender combinations (no. patients)
Recipient male/donor female 8 4 5
Recipient male/donor male 22 5 16
Recipient female/donor female 18 6 11 .40
Recipient female/donor male 16 1 15
ALL
t(9;22) (no. patients) (percentage) 48 (75%) 9 (56%) 40 (85%)
t(4;11) 14 (22%) 4 (25%) 7 (15%) .03
t(1;19) 2 (3%) 3 (19%) —
WBC at diagnosis (3 109/L)
(median, range) 25 (2-631) 10 (2-732) 52 (2-870) .26
Percentage of blasts at BMT
(median, range) 0.4 (0-5) 1.2 (0-5) 50 (0-95) , .0001
Time from diagnosis to BMT (mo) 7 (4-19) 19 (7-124) 9 (4-43) , .0001
Time from CR1 to BMT (mo) 5 (0-17) 15 (5-124) — , .0001
Karnofsky score 90-100 (percentage) 53 (83%) 9 (56%) 15 (32%) , .0001
CMV-serology donor/recipient (no. patients)
1/1 13 2 14
2/1 15 3 13 .56
1/2 13 5 7
2/2 (percentage) 23 (36%) 6 (38%) 12 (26%)
Conditioning regimen (no. patients) (%)
Cy/TBI 37 (88%) 6 (69%) 24 (72%)
Cy/TBI 1 Ara-C or VP16 19 5 10 .18
Other 8 5 13
Cell dose (3 108/kg) (range)
TCD 0.6 (0.1-3.6) 0.4 (0.1-0.7) 1.0 (0.2-1.6) .18
non-TCD 2.4 (0.6-8.1) 3.0 (0.2-4.8) 3.1 (0.5-6.7) .74
Matched at A, B, DRB1 (no. patients) 42 10 26 .58
Single mismatch at A, B or DR (no. patients) 22 6 21
ALL indicates acute lymphoblastic leukemia; WBC, white blood cell; BMT, bone marrow transplantation; CMV, cytomegalovirus; Cy, cyclophosphamide; TBI, total body
irradiation; Ara-C, cytarabin; VP16, etoposide; TCD, T cell depleted.
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no data for these end points were available. However, baseline data and OS
were reported for these 2 CR1 patients, so OS could be estimated for 127
patients and Table 1 presents characteristics of 127 patients.
Engraftment was defined as the first of 3 consecutive days when the
absolute neutrophil count (ANC) exceeded 0.5 3 09/L. Primary graft
failure was defined by a lack of neutrophil engraftment in patients surviving
at least 28 days. Secondary graft failure was defined as neutrophil recovery
followed by a decline in ANC to below 0.5 3 109/L for 3 consecutive days.
Acute and chronic GVHD were diagnosed and graded according to
consensus criteria.22 Chronic GVHD was evaluated among patients who
survived at least 100 days after transplantation. Definition of DFS, OS,
TRM, and relapse were according to standard criteria.23
Results of the study were analyzed as of December 1999. Patient
characteristics in the cohorts presented were compared using either the
Fisher exact test (for discrete variables) or Wilcoxon rank test (for
continuous variables). Table 2 shows the variables that were examined in
the univariate and multivariable analyses. In the univariate analysis, OS and
DFS were compared using Kaplan-Meier curves. Acute GVHD, chronic
GVHD, and relapse were calculated using cumulative incidence,24 with
death treated as a competing risk. TRM was also calculated using
cumulative incidence, with relapse treated as a competing risk. The
multivariable analysis for each end point used the Cox proportional hazards
model. A significance level of a 5 0.05 was used for all analyses.
Results
Engraftment
One hundred and eight patients survived beyond the first 28 days
after transplantation. Of these 108 patients, 102 showed myeloid
engraftment, which was sustained in 90 patients. Nineteen patients
died during the first 28 days, of whom 11 patients had already
engrafted. Incidences of primary and secondary graft failure were
6% 6 4% and 7% 6 6%, respectively. Transplantation in CR1 and
a lower WBC at diagnosis were associated with a higher incidence
of sustained engraftment following multivariable analysis.
OS and DFS
Overall survival at 2 years from transplantation was 40% 6 13%
for patients undergoing BMT in CR1 and 32% 6 16% at 4 years.
When estimated as competing risk factors for OS, relapse mortality
and TRM were 6% 6 7% and 54% 6 13%, respectively (Figure
1). Currently, 23 CR1 patients are alive and disease free with a
median follow-up of 24 months (range, 3-97) and 13 CR1 patients
have survived beyond 2 years after BMT. OS was 17% for patients
in CR2/3 and 5% for patients with refractory ALL at 2 years after
BMT. The competing factors relapse mortality and TRM were,
respectively, 8% and 75% for CR 2/3 patients and 31% and 64% for
refractory patients at 2 years after BMT. Of the 127 patients
analyzed, 28 patients are currently alive with a median follow-up of
24 months (range, 3-97).
Overall survival and DFS were most favorably affected by remission
status (Figure 2, Table 3). Following multivariable Cox regression
analysis, the translocation t(9;22) was also associated with better DFS,
which variable showed no interaction with remission status. In addition,
a shorter interval from diagnosis to BMT, matching forA, B, and DRB1,
and cytomegalovirus (CMV) seronegativity appeared as independent
prognostic factors associated with better DFS. The question whether
results had improved in recent years was addressed in univariate and
multivariable analysis. DFS was 27% 6 10% for 77 patients undergo-
ing BMT between 1996 and 1999 and DFS was 13% 6 9% for 48
patients having transplantation before 1996 (P 5 .07 by log-rank
analysis). However, when forced into the model for multivariable
analysis as a continuous variable, no improvement of DFS in recent
years could be demonstrated.
Figure 1. Overall survival in CR1, as determined by the competing risk factors
relapse mortality and treatment-related mortality.
Figure 2. Kaplan-Meier estimate of DFS. The survival difference between CR1
patients versus others was highly significant (P 5 .0001).
Table 2. Parameters considered for the univariate and multivariable models
Patient data:
Age*
Karnofsky score†
CMV serology†
Disease data:
WBC count at diagnosis (3 109/L)*
Cytogenetics†
BM blasts at BMT (%)*
Disease stage at BMT†
Time from diagnosis to BMT*
Donor data:
Age*
CMV serology†
Transplant data:
Year of transplant*
HLA matching†
TBI applied†
Ara-C or VP-16 added to TBI†
Marrow cell dose*
T-cell depletion†
MTX 1 CSA included for GVH prophylaxis†
ALG included in conditioning†
CMV indicates cytomegalovirus; TBI, total body irradiation; Ara-C, cytarabin;
VP-16, etoposide; MTX 1 CSA, methotrexate 1 cyclosporin A; GVH, graft-versus-
host; ALG, antilymphocyte globulin.
Continuous variables were treated as categorical in the univariate analysis,
typically with the variables split at their medians.
*Continuous variable.
†Categorical variable.
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Relapse
The cumulative incidence of relapse was 19% 6 7% at 4 years after
BMT and 13% 6 10% versus 30% 6 9% for CR1 and refractory
patients, respectively (Figure 3, P 5 .001). Twenty-one of a total of 23
relapses had occurred during the first year after BMT. Only one relapse
occurred among the 17 patients who received BMT in CR1 and
survived for at least 1 year, with a median follow-up of 25 months
(range, 12-109). A higher relapse rate was observed in refractory ALL,
which appeared as the most significant variable (hazard ratio: 9.29,
P , .0001, Table 3, Figure 3) affecting relapse by multivariable
analysis. In addition, fewer relapses occurred in patients with Ph1 ALL
(hazard ratio: 0.33, P 5 .05), as compared to patients with t(4;11) or
t(1;19), which effect appeared independent from remission status. Four
patients, including 3 with t(9;22) ALL, with relapse were treated with
donor leukocyte infusions (DLI), and 2 Ph1 patients achieved a
complete response.
TRM
Cumulative incidence of TRM was 61% 6 9 at 2 years from transplan-
tation and 54% 6 13% versus 64% 6 13% for CR1 and refractory
patients, respectively (not significant, Figure 4). The following prognos-
tic factors were associated with less TRM: Karnofsky score 90 or above;
HLA matching for A, B, and DRB1; CMV seronegativity; and a higher
cell dose for patients receiving non-TCD grafts (Table 3). Age appeared
not to be associated with TRM in this group of patients. A shorter
interval from diagnosis to BMT predicted for less TRM, which proved
independent from remission status. Although TCD was associated with
less GVHD, no reduction of TRM could be observed in patients
receiving a TCD graft. Again, year of transplant was evaluated for a
possible association with TRM. However, no reduction of TRM could
be demonstrated in recent years, when year of transplant was included as
2 categories (below or above the median) in univariate analysis, or as a
continuous variable in multivariable analysis. Fifty-seven patients died
due to TRM before day 100 after BMT and 25 (44%) of them had been
diagnosed with grade III-IV acute GVHD. Seventeen patients died due
to TRM after day 100 and 6 (35%) of the latter suffered from extensive
chronic GVHD. Causes of death included opportunistic infections
(n 5 25), respiratory insufficiency due to lung toxicity/pneumonia
without a demonstrated causative infectious etiology (n 5 7), single
organ toxicity (respiratory failure excluded; n 5 24), GVHD (n 5 14),
hemorrhages (n 5 15), and graft failure (n 5 4).
GVHD
Cumulative incidences of grade II-IV and grade III-IV acute GVHD
were 50% 6 8% and 31% 6 8% at 100 days after BMT. Higher
cumulative incidences at day 100 of grade II-IV of acute GVHD were
observed in CMV-seropositive patients (60% 6 12%) versus CMV-
seronegative patients (40% 6 12%), in patients receiving non-TCD
grafts versus TCD-BMT (55% 6 10% and 33% 6 16%, respectively),
and in patients receiving TBI-based conditioning versus those condi-
tioned with chemotherapy (52% 6 9% and 25% 6 24%, respectively).
In multivariable analysis, a positive CMV serostatus was significantly
associated with an increased risk of grade III-IV acute GVHD (relative
risk, 4.87; P , .0001). Fifty-six patients survived at least 100 days after
Table 3. Results of the multivariable analyses
Parameter
Disease-free survival Treatment-related mortality Relapse
RR 95% Cl P value RR 95% Cl P value RR 95% Cl P value
First remission 1.00 NA 1.00 NA 1.00 NA
CR 2/3 1.38 (0.64-2.97) .40 1.01 (0.42-2.44) 0.98 3.20 (0.61-16.64) .17
Relapse/PIF 2.85 (1.73-4.68) , .0001 1.16 (0.63-2.13) 0.64 9.29 (3.23-26.70) , .0001
t(9;22) 0.49 (0.30-0.82) .006 — — — 0.33 (0.11-1.00) .05
Time from diagnosis to BMT* 1.33 (1.08-1.63) .008 1.31 (1.05-1.63) 0.009 —
HLA-A, -B, or -DRB1 mismatched 1.76 (1.10-2.83) .02 2.28 (1.26-4.12) 0.006 —
CMV serology (pat-, don-) 0.62 (0.38-1.00) .05 0.43 (0.23-0.80) 0.008 —
Karnofsky score $ 90 — — 0.41 (0.23-0.74) 0.003 —
Cell dose:
TCD — — 0.45 (0.18-1.17) 0.10 —
non-TCD — — 0.79 (0.64-0.96) 0.02 —
RR indicates relative risk; Cl, confidence interval; NA, not applicable; CR, complete remission; PIF, primary induction failure; CMV, cytomegalovirus; TCD, T-cell depletion.
*RR, expressed per year.
Figure 3. Cumulative incidences of relapse in CR1, CR2/3, and refractory
poor-risk ALL following unrelated donor BMT.
Figure 4. Cumulative incidences of TRM after unrelated donor BMT in poor-risk
ALL. Results were not significantly different for CR1, versus CR2/3, versus
refractory ALL.
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BMT; the cumulative incidence of chronic extensive GVHD was
48% 6 13% at 2 years after BMT. Only a higher Karnofsky score
favorably affected the incidence of chronic GVHD following multivari-
able analysis.
Discussion
In this report, we demonstrate that transplantation of matched
unrelated donor marrow results in favorable long-term DFS in
adult patients with poor-risk ALL in CR1. DFS observed in patients
with PIF or allografted in relapse or beyond CR1 was significantly
less, which appeared to be due primarily to transplant-related
complications.
Sixty-two patients transplanted in CR1 showed an OS of
40% 6 13% at 2 years after transplantation, which compares well
to results obtained in poor-risk ALL following HLA-identical
sibling BMT as reported by single centers and by the IBMTR.13-19
In our group of patients, relapse mortality and TRM accounted for
loss of OS by 6% 6 7% and 54% 6 13%, respectively, when
estimated as competing risk factors for OS. Only 7 patients
developed a relapse and currently 23 CR1 patients are alive and
free of disease with a median follow-up of 24 months. The
observed incidence of relapse seems similar or possibly less
compared to what has been observed following allogeneic sibling
BMT in poor-risk ALL. In various studies, some of which also
included younger patients, the relapse rate following sibling BMT
varied between 9% and 34%.13-19 Only limited data are available
with respect to relapse following unrelated BMT in poor-risk ALL.
No relapses were observed in 7 CR1 patients (including 2 younger
patients) reported by Sierra et al,25 and 3 of 9 younger patients were
reported to have a relapse following a TCD unrelated donor BMT
for CR1 Ph1 ALL.26 Recently, Arico and coworkers reported data
on 326 children with Ph1 ALL, including 21 who received an
unrelated donor BMT, which was followed by a relapse in 4 of
these 21 children.27 A possible enhanced graft-versus-leukemia
(GVL) effect following unrelated BMT might be explained by the
difference of HLA compatibility between HLA genotypically
identical siblings versus unrelated donors, who are matched for A,
B, and DRB1. Mismatches at HLA-C, -DQB1, and -DPB1
frequently occur and may also be associated with GVHD and
GVL.28,29 As many as 50% of donor and recipient pairs apparently
matched for HLA-A and -B, using serologic typing methods, have
one or more incompatibilities at A, B, or C alleles by DNA
sequencing.28 Mismatches for DQB1 and DPB1 occur in approxi-
mately 80% of A, B, C, and DRB1 allele matched pairs, predomi-
nantly because of DPB mismatch due to the poor linkage disequilib-
rium between DQ and DP loci.28,30-33
Despite the low relapse rate observed, a more exact estimate of the
GVL effect for comparison with sibling BMT cannot be given because a
relatively high percentage of patients in this study died of TRM and,
therefore, were not at risk for relapse. Nevertheless, our findings do
indicate a strong GVL effect because relapse rates after autologous stem
cell transplantation or intensive chemotherapy have been reported to
exceed 50%.12,13,16-18,27,34 Furthermore, apart from the low relapse rate
as such, the GVL effect is further supported by the complete responses
following donor lymphocyte infusion observed by us and others as
well.35,36 Patients with Ph1 ALL seem to be particularly susceptible for
GVL effect, because we found significantly fewer relapses in Ph1 ALL
as compared to ALL patients with t(4;11) or t(1;19), which translated in
better DFS (Table 3).
Survival in this study was mainly determined by TRM. Cumulative
incidence of TRM was 61% 6 9% for all patients and did not differ
significantly for refractory patients versus patients in remission at the
time of BMT (Figure 4). TRM in adult patients clearly exceeds TRM in
children following unrelated BMT or following sibling BMT. Recent
studies have shown that innovations in supportive care, such as
improved prophylaxis for fungal and viral infections, as well as
improved molecular techniques and criteria for HLA matching have
resulted in less TRM in recent years, both following unrelated BMT and
sibling donor BMT.29,37-39 However, when we evaluated whether results
in this group of patients improved during a 10-year period, no such
effect could be demonstrated. It may be explained by a persistent and
overruling effect of time from diagnosis to BMT as an important risk
factor for TRM and DFS. The median time from diagnosis to BMT was
8 months and that interval strongly affected TRM (independent from
remission status), but not relapse (Table 3). This increased risk for TRM
may be explained by the length and intensity of the preceding
chemotherapy, which may add to the risk for lethal complications after
BMT. Considering the high incidence of lethal complications in patients
with refractory ALL added to an already higher relapse risk, unrelated
donor BMT should not be encouraged in patients with refractory ALL.
Opportunistic infections and respiratory insufficiency accounted for
the majority of lethal complications. Because a minority of patients
dying due to TRM suffered from severe acute or chronic GVHD, our
findings suggest that an impaired immune recovery rather than GVHD
put the patients at risk for severe infections. An impaired immune
recovery is further supported by increased TRM in CMV-seropositive
patients, whereas CMV-pneumonia as the cause of death was observed
in only one patient. We recently reported that CMV may still affect TRM
despite effective prevention of CMV disease. This effect seems selec-
tively to occur in severe immunocompromised patients, such as elderly
patients, or patients receiving TCD grafts.40
How can the relatively high TRM be improved? The different
prognostic variables associated with TRM clearly indicate that
reduction of TRM may follow upon reduction in the interval
between diagnosis and transplant and avoid cumulative toxicity of
successive cytotoxic agents. The latter aim may very well be
achieved by incorporating relatively less toxic and highly active
new agents such as the novel tyrosine kinase inhibitor STI41 in
induction therapy for patients with Ph1 ALL. In addition, donor
searches should start early to be able to perform BMT shortly after
achieving remission. Furthermore, as reported before, we observed
less TRM in patients receiving larger stem cell grafts. Therefore,
increasing the cell dose, which may enhance neutrophil and
lymphocyte recovery,42 may further reduce the susceptibility for
opportunistic infections in this category of patients.
In conclusion, despite a relatively high incidence of lethal opportunis-
tic infections and pulmonary complications, survival following unre-
lated donor BMT in poor-risk ALL patients in CR1 is encouraging and
compares favorably to results obtained following intensive chemo-
therapy or autologous transplantation (or both) due to an apparently
strong GVL effect. Immediate donor search and careful timing of
transplantation directly upon achieving remission as well as procuring
larger stem cell grafts, from fully HLA-matched donors, may further
improve the outcome of unrelated donor BMT in poor-risk ALL.
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